Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SAFESKIN -- Ignore unavailable to you. Want to Upgrade?

To: Dave Twibell who wrote (661)	3/11/1999 6:08:00 PM
From: Beltropolis Boy	Respond to of 828

>There seems to be a pretty important discrepancy between the press release Chris posted and the summary in Briefing.com. dave. i believe robert has it pegged. to wit (bolding mine): "Safeskin's sales are expected to be approximately $28 million below analysts' expectations for the first quarter.... It is anticipated that these events will reduce earnings in the first quarter by approximately $0.25 - $0.26 per share below analysts' expectations." and under FULL YEAR 1999 IMPACT: "Safeskin estimates that sales for the year will be lower by approximately an additional $25 million." so, to me, total FY99 revenue is down roughly $58M. and that probably equates to about $0.50 a share. -chris.

To: Dave Twibell who wrote (661)	3/11/1999 6:11:00 PM
From: Robert Lawkins	Read Replies (2) \| Respond to of 828

Well, a $25 million shortfall in sales at a 50% margin would reduce the net by about $12.5 million which would be about $0.23/share (with 55 million shares out) Roughly speaking. I don't think it will be good but not as bad as some are saying. The stock has already suffered under heavy volume. I'm hoping the worst is over.

To: Dave Twibell who wrote (661)	3/11/1999 7:54:00 PM
From: kendall harmon	Read Replies (1) \| Respond to of 828

Robert, I think this Bloomberg piece may help answer your question. San Diego, March 11 (Bloomberg) -- Safeskin Corp., the largest U.S. manufacturer of disposable latex examination gloves, said its first-quarter earnings will be well below analyst expectations because of lower sales. The San Diego-based company said it will have earnings of 1 cent to 2 cents in the quarter ending March 31. It was expected to earn 27 cents, the average estimate of six analysts surveyed by First Call Corp. Safeskin said overproduction and pressure to lower prices hurt revenue and earnings. It said sales will be about $28 million below analyst expectations for the quarter and $53 million below for the full year. It said its gross margins will decline between 4 percent and 6 percent by the end of the year to between 46 percent and 48 percent. ''It's a challenging market because of the pricing pressures,'' said John Arege, an analyst at S&P Equity Group, who downgraded Safeskin to ''hold'' from ''buy.'' He expected revenue of about $66 million for the quarter. Safeskin shares fell 2 3/4, or 15 percent, to 15 1/4 in trading of 6.6 million, six times the three-month daily average, before trading was halted in early afternoon. The company was founded in 1987, when the U.S. Centers for Disease Control recommended that health-care workers wear gloves to protect themselves from HIV, the virus that causes AIDS. Safeskin, which does its manufacturing in Asia, controls about 20 percent of the U.S. market for gloves. Safeskin had revenue of $237 million in 1998.